We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassays for Enzyme and Inhibitors Predict Breast Cancer

By LabMedica International staff writers
Posted on 01 Mar 2011
Print article
Immunoenzymatic assays have been used to detect serum concentrations of matrix metalloproteinases (MMPs) and their tissue inhibitors in patients with breast cancer.

Serum levels of MMP-2, family of zinc-dependent endopeptidases and the endogenous inhibitors of MMPs, the tissue inhibitors of metalloproteinases (TIMPs) can be measured either by profiling kits and enzyme linked immunosorbent assays (ELISA).

A study carried out at the University of Athens, (Athens, Greece), examined the serum concentration of the enzymes and inhibitors from a cohort of women with nonpalpable breast lesions who were followed for 24 months. Serum MMP-2 concentrations were measured using Fluorokine MultiAnalyte Profiling kits in a Luminex Bioanalyzer (Luminex Corp, TX, USA). Levels of the inhibitors TIMP-1 and TIMP-2 and other tumor markers were assessed using ELISA methods.

The scientists assessed serum concentrations of MMP1, MMP-2, TIMP-1, and TIMP-2 in atypical ductal hyperplasia (ADH), lobular neoplasia (LN), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) specifically in nonpalpable breast lesions found after mammography. The serum TIMPs and other tumor markers were assessed by ELISA methods from R&D Systems, (Minneapolis, MN, USA), and IDL Biotech AB, (Bromma, Sweden).

Serum TIMP-2 concentrations were positively associated with the severity of the lesion. Conversely, MMP-2 levels were marginally negatively associated with severity; as evident, the MMP-2/TIMP-2 ratio significantly decreased along with severity. No significant associations were demonstrated between the other biomarkers tested and breast cancer carcinogenesis. The MMP-2 serum levels and the MMP-2/TIMP-2 ratio were significantly higher in the LN subgroup compared with the ADH subgroup.

The authors concluded that TIMP-2 was associated with more severe diagnosis in nonpalpable lesions and that the MMP-2/TIMP-2 ratio may exhibit meaningful changes along with progression of lesions. Extracellular cell matrix remodeling in ductal and lobular lesions appears to follow distinct patterns. The study has been available online since December 3, 2010, in the journal Clinica Chimica Acta.

Related Links:

University of Athens
Luminex Corp.
R&D Systems
IDL Biotech AB


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.